Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia a randomized clinical trial

Jeffrey L. Cummings, Constantine G Lyketsos, Elaine R. Peskind, Anton P. Porsteinsson, Jacobo E. Mintzer, Douglas W. Scharre, Jose E. De La Gandara, Marc Agronin, Charles S. Davis, Uyen Nguyen, Paul Shin, Pierre N. Tariot, João Siffert

Research output: Contribution to journalArticle

Abstract

IMPORTANCE Agitation is common among patients with Alzheimer disease; safe, effective treatments are lacking. OBJECTIVE To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for Alzheimer disease-related agitation. DESIGN, SETTING, AND PARTICIPANTS Phase 2 randomized, multicenter, double-blind, placebo-controlled trial using a sequential parallel comparison design with 2 consecutive 5-week treatment stages conducted August 2012-August 2014. Patients with probable Alzheimer disease, clinically significant agitation (Clinical Global Impressions-Severity agitation score≥4), and a Mini-Mental State Examination score of 8 to 28 participated at 42 US study sites. Stable dosages of antidepressants, antipsychotics, hypnotics, and antidementia medications were allowed. INTERVENTIONS In stage 1, 220 patients were randomized in a 3:4 ratio to receive dextromethorphan-quinidine (n = 93) or placebo (n = 127). In stage 2, patients receiving dextromethorphan-quinidine continued; those receiving placebo were stratified by response and rerandomized in a 1:1 ratio to dextromethorphan-quinidine (n = 59) or placebo (n = 60). MAIN OUTCOMES AND MEASURES The primary end pointwas change from baseline on the Neuropsychiatric Inventory (NPI) Agitation/Aggression domain (scale range, 0 [absence of symptoms] to 12 [symptoms occur daily and with marked severity]). RESULTS Atotal of 194 patients (88.2%) completed the study. With the sequential parallel comparison design, 152 patients received dextromethorphan-quinidine and 127 received placebo during the study. Analysis combining stages 1 (all patients) and 2 (rerandomized placebo nonresponders)showedsignificantlyreducedNPIAgitation/Aggressionscoresfordextromethorphanquinidinevsplacebo( ordinaryleastsquareszstatistic,-3.95;P <.001).Instage1,meanNPIAgitation/ Aggression scoreswere reduced from 7.1 to 3.8 with dextromethorphan-quinidine and from 7.0to 5.3withplacebo.Between-grouptreatmentdifferencesweresignificantinstage1(leastsquaresmean, -1.5; 95%CI, -2.3 to -0.7; P

Original languageEnglish (US)
Pages (from-to)1242-1254
Number of pages13
JournalJournal of the American Medical Association
Volume314
Issue number12
DOIs
StatePublished - Sep 22 2015

Fingerprint

Dextromethorphan
Quinidine
Alzheimer Disease
Randomized Controlled Trials
Placebos
Aggression
Hypnotics and Sedatives
Antidepressive Agents
Antipsychotic Agents
Outcome Assessment (Health Care)
Safety
Equipment and Supplies
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia a randomized clinical trial. / Cummings, Jeffrey L.; Lyketsos, Constantine G; Peskind, Elaine R.; Porsteinsson, Anton P.; Mintzer, Jacobo E.; Scharre, Douglas W.; De La Gandara, Jose E.; Agronin, Marc; Davis, Charles S.; Nguyen, Uyen; Shin, Paul; Tariot, Pierre N.; Siffert, João.

In: Journal of the American Medical Association, Vol. 314, No. 12, 22.09.2015, p. 1242-1254.

Research output: Contribution to journalArticle

Cummings, JL, Lyketsos, CG, Peskind, ER, Porsteinsson, AP, Mintzer, JE, Scharre, DW, De La Gandara, JE, Agronin, M, Davis, CS, Nguyen, U, Shin, P, Tariot, PN & Siffert, J 2015, 'Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia a randomized clinical trial', Journal of the American Medical Association, vol. 314, no. 12, pp. 1242-1254. https://doi.org/10.1001/jama.2015.10214
Cummings, Jeffrey L. ; Lyketsos, Constantine G ; Peskind, Elaine R. ; Porsteinsson, Anton P. ; Mintzer, Jacobo E. ; Scharre, Douglas W. ; De La Gandara, Jose E. ; Agronin, Marc ; Davis, Charles S. ; Nguyen, Uyen ; Shin, Paul ; Tariot, Pierre N. ; Siffert, João. / Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia a randomized clinical trial. In: Journal of the American Medical Association. 2015 ; Vol. 314, No. 12. pp. 1242-1254.
@article{cb25586cdd6c4d5b9854c7a019db4dad,
title = "Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia a randomized clinical trial",
abstract = "IMPORTANCE Agitation is common among patients with Alzheimer disease; safe, effective treatments are lacking. OBJECTIVE To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for Alzheimer disease-related agitation. DESIGN, SETTING, AND PARTICIPANTS Phase 2 randomized, multicenter, double-blind, placebo-controlled trial using a sequential parallel comparison design with 2 consecutive 5-week treatment stages conducted August 2012-August 2014. Patients with probable Alzheimer disease, clinically significant agitation (Clinical Global Impressions-Severity agitation score≥4), and a Mini-Mental State Examination score of 8 to 28 participated at 42 US study sites. Stable dosages of antidepressants, antipsychotics, hypnotics, and antidementia medications were allowed. INTERVENTIONS In stage 1, 220 patients were randomized in a 3:4 ratio to receive dextromethorphan-quinidine (n = 93) or placebo (n = 127). In stage 2, patients receiving dextromethorphan-quinidine continued; those receiving placebo were stratified by response and rerandomized in a 1:1 ratio to dextromethorphan-quinidine (n = 59) or placebo (n = 60). MAIN OUTCOMES AND MEASURES The primary end pointwas change from baseline on the Neuropsychiatric Inventory (NPI) Agitation/Aggression domain (scale range, 0 [absence of symptoms] to 12 [symptoms occur daily and with marked severity]). RESULTS Atotal of 194 patients (88.2{\%}) completed the study. With the sequential parallel comparison design, 152 patients received dextromethorphan-quinidine and 127 received placebo during the study. Analysis combining stages 1 (all patients) and 2 (rerandomized placebo nonresponders)showedsignificantlyreducedNPIAgitation/Aggressionscoresfordextromethorphanquinidinevsplacebo( ordinaryleastsquareszstatistic,-3.95;P <.001).Instage1,meanNPIAgitation/ Aggression scoreswere reduced from 7.1 to 3.8 with dextromethorphan-quinidine and from 7.0to 5.3withplacebo.Between-grouptreatmentdifferencesweresignificantinstage1(leastsquaresmean, -1.5; 95{\%}CI, -2.3 to -0.7; P",
author = "Cummings, {Jeffrey L.} and Lyketsos, {Constantine G} and Peskind, {Elaine R.} and Porsteinsson, {Anton P.} and Mintzer, {Jacobo E.} and Scharre, {Douglas W.} and {De La Gandara}, {Jose E.} and Marc Agronin and Davis, {Charles S.} and Uyen Nguyen and Paul Shin and Tariot, {Pierre N.} and Jo{\~a}o Siffert",
year = "2015",
month = "9",
day = "22",
doi = "10.1001/jama.2015.10214",
language = "English (US)",
volume = "314",
pages = "1242--1254",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia a randomized clinical trial

AU - Cummings, Jeffrey L.

AU - Lyketsos, Constantine G

AU - Peskind, Elaine R.

AU - Porsteinsson, Anton P.

AU - Mintzer, Jacobo E.

AU - Scharre, Douglas W.

AU - De La Gandara, Jose E.

AU - Agronin, Marc

AU - Davis, Charles S.

AU - Nguyen, Uyen

AU - Shin, Paul

AU - Tariot, Pierre N.

AU - Siffert, João

PY - 2015/9/22

Y1 - 2015/9/22

N2 - IMPORTANCE Agitation is common among patients with Alzheimer disease; safe, effective treatments are lacking. OBJECTIVE To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for Alzheimer disease-related agitation. DESIGN, SETTING, AND PARTICIPANTS Phase 2 randomized, multicenter, double-blind, placebo-controlled trial using a sequential parallel comparison design with 2 consecutive 5-week treatment stages conducted August 2012-August 2014. Patients with probable Alzheimer disease, clinically significant agitation (Clinical Global Impressions-Severity agitation score≥4), and a Mini-Mental State Examination score of 8 to 28 participated at 42 US study sites. Stable dosages of antidepressants, antipsychotics, hypnotics, and antidementia medications were allowed. INTERVENTIONS In stage 1, 220 patients were randomized in a 3:4 ratio to receive dextromethorphan-quinidine (n = 93) or placebo (n = 127). In stage 2, patients receiving dextromethorphan-quinidine continued; those receiving placebo were stratified by response and rerandomized in a 1:1 ratio to dextromethorphan-quinidine (n = 59) or placebo (n = 60). MAIN OUTCOMES AND MEASURES The primary end pointwas change from baseline on the Neuropsychiatric Inventory (NPI) Agitation/Aggression domain (scale range, 0 [absence of symptoms] to 12 [symptoms occur daily and with marked severity]). RESULTS Atotal of 194 patients (88.2%) completed the study. With the sequential parallel comparison design, 152 patients received dextromethorphan-quinidine and 127 received placebo during the study. Analysis combining stages 1 (all patients) and 2 (rerandomized placebo nonresponders)showedsignificantlyreducedNPIAgitation/Aggressionscoresfordextromethorphanquinidinevsplacebo( ordinaryleastsquareszstatistic,-3.95;P <.001).Instage1,meanNPIAgitation/ Aggression scoreswere reduced from 7.1 to 3.8 with dextromethorphan-quinidine and from 7.0to 5.3withplacebo.Between-grouptreatmentdifferencesweresignificantinstage1(leastsquaresmean, -1.5; 95%CI, -2.3 to -0.7; P

AB - IMPORTANCE Agitation is common among patients with Alzheimer disease; safe, effective treatments are lacking. OBJECTIVE To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for Alzheimer disease-related agitation. DESIGN, SETTING, AND PARTICIPANTS Phase 2 randomized, multicenter, double-blind, placebo-controlled trial using a sequential parallel comparison design with 2 consecutive 5-week treatment stages conducted August 2012-August 2014. Patients with probable Alzheimer disease, clinically significant agitation (Clinical Global Impressions-Severity agitation score≥4), and a Mini-Mental State Examination score of 8 to 28 participated at 42 US study sites. Stable dosages of antidepressants, antipsychotics, hypnotics, and antidementia medications were allowed. INTERVENTIONS In stage 1, 220 patients were randomized in a 3:4 ratio to receive dextromethorphan-quinidine (n = 93) or placebo (n = 127). In stage 2, patients receiving dextromethorphan-quinidine continued; those receiving placebo were stratified by response and rerandomized in a 1:1 ratio to dextromethorphan-quinidine (n = 59) or placebo (n = 60). MAIN OUTCOMES AND MEASURES The primary end pointwas change from baseline on the Neuropsychiatric Inventory (NPI) Agitation/Aggression domain (scale range, 0 [absence of symptoms] to 12 [symptoms occur daily and with marked severity]). RESULTS Atotal of 194 patients (88.2%) completed the study. With the sequential parallel comparison design, 152 patients received dextromethorphan-quinidine and 127 received placebo during the study. Analysis combining stages 1 (all patients) and 2 (rerandomized placebo nonresponders)showedsignificantlyreducedNPIAgitation/Aggressionscoresfordextromethorphanquinidinevsplacebo( ordinaryleastsquareszstatistic,-3.95;P <.001).Instage1,meanNPIAgitation/ Aggression scoreswere reduced from 7.1 to 3.8 with dextromethorphan-quinidine and from 7.0to 5.3withplacebo.Between-grouptreatmentdifferencesweresignificantinstage1(leastsquaresmean, -1.5; 95%CI, -2.3 to -0.7; P

UR - http://www.scopus.com/inward/record.url?scp=84942241583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942241583&partnerID=8YFLogxK

U2 - 10.1001/jama.2015.10214

DO - 10.1001/jama.2015.10214

M3 - Article

VL - 314

SP - 1242

EP - 1254

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 12

ER -